Use of Germline and Somatic Molecular Testing in Prostate Cancer Diagnosis

Posted by Guilherme Godoy, MD, MS | Nov 2020

Guilherme Godoy, MD, MPH, presented “Use of Germline and Somatic Molecular Testing in Prostate Cancer Diagnosis” virtually during the Innovations in Urologic Practice 2020 virtual conference in September 2020.

How to cite: Godoy, Guilherme. “Use of Germline and Somatic Molecular Testing in Prostate Cancer Diagnosis” September 26th, 2020. Accessed Apr 2024. https://use-of-germline-and-somatic-molecular-testing-in-prostate-cancer-diagnosis/

Summary:

Guilherme Godoy, MD, MPH, Assistant Professor of Urology and Urology Oncology at Baylor College of Medicine in Houston, Texas, provides an overview of research done regarding germline and somatic testing for prostate cancer diagnosis and treatment over the past decade plus. He discusses the difference between germline and somatic tests, the applications of these tests, the kinds of tests available, and testing criteria guidelines. Dr. Godoy then lists the most important genes, including HOXB13, the HBOC genes, and the genes connected to Lynch Syndrome, among others, and discusses their association with greater risk of earlier-onset, deadlier prostate cancer. Dr. Godoy concludes by going over the conclusions of the 2019 Philadelphia Prostate Cancer Consensus Conference, which sought to define ideal strategies for genetic testing clinical implementation, to define clinical and treatment indications based on these tests, and to propose alternative strategies to meet increased demand for genetic counseling.

About the Innovations in Urologic Practice 2020 virtual conference:
Presented by co-chairs Mohit Khera, MD, MBA, MPH, and Michael Coburn, MD, FACS, the Innovations in Urologic Practice conference provides a detailed review and commentary on multiple genitourinary and urologic diseases. Among the featured oncological topics are bladder cancer and immunotherapies, as well as upper tract cancer management, prostate cancer, including state-of-the-art imaging, focal therapy, and MRI. Experts also discuss new tools and techniques for nephrectomy and treating advanced renal cell carcinoma. In terms of general urological approaches, conference also include pelvic reconstruction and trauma, men’s health topics like male infertility and sexual dysfunction, and ways to diagnose and treat infections in the urology patient. Dr. Godoy presented this talk virtually at this year’s conference.

About The Author

Guilherme Godoy, MD, MS

Guilherme Godoy, MD, MS, serves as assistant professor of urology at the Baylor College of Medicine (BCM) in Houston, Texas. He joined the faculty of the Scott Department of Urology at BCM in 2012 and has been the chief of the urology service at Ben Taub General Hospital (Harris Health System), since 2017. Dr. Godoy earned his medical degree from Fundacao Universitaria do ABC in Sao Paulo, Brazil. His training includes an internship and residency in urology at Santa Casa De Sao Paulo in Vila Buarque, Brazil, and a fellowship in urologic oncology at BCM. Dr. Godoy has also completed urologic oncology fellowship training at Vancouver General Hospital, New York University, and Memorial Sloan-Kettering Cancer Center. He earned his MS in clinical investigations at BCM and has remained active in clinical research, translational studies, and clinical trials, mostly focused on prostate, urothelial (upper and lower urinary tract), and testicular cancers. Dr. Godoy’s expertise includes early diagnosis, minimally invasive approaches (endoscopic and robotic), utilization of molecular and genetic tools for personalized decision-making, management of hereditary cancers, and surgical management of complex/large genitourinary (GU) tumors. His clinical areas of interest include adrenal and kidney tumors, urothelial cancers (upper and lower urinary tract including ureter, renal pelvis, bladder, and urethra), prostate cancer, penile cancer, and testicular and paratesticular cancers. Dr. Godoy also specializes in the utilization of intestinal segments for urinary tract reconstructions, and coordination of multidisciplinary approaches to manage complex intra-abdominal, retroperitoneal, and pelvic tumors. Dr. Godoy is responsible for and moderates the GU Tumor Board Meetings at Baylor St. Luke’s Medical Center as well as the St. Luke’s International GU Tumor Board Meetings.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat